Watch the lecture by Professor Javed Butler and explore the benefits of early sodium-glucose cotransporter 2 inhibitor initiation for heart failure patients, both in the acute and chronic settings, in improving CV and hospitalization outcomes and mitigating the damage of upstream cardio-renal-metabolic (CRM) risk factors.

In a recent lecture, Dr. Cheng Yuk Yan, Alice, emphasizes the importance of early and comprehensive screening for CKM syndrome. Dr. Cheng advocated for initiating empagliflozin early and noted that any specialist who recognizes the need should consider initiating it. This approach is supported by trials like the EMPA-REG OUTCOME, EMPA-KIDNEY, and the EMPEROR trials. These studies helped establish empagliflozin as a foundational "organ-protecting" therapy, which is now recommended in major international guidelines.

This lecture emphasizes the urgent need for early detection and intervention in CKD, noting that even mild cases require prompt action, including consideration of SGLT2 inhibitors like empagliflozin, which have demonstrated the potential to significantly delay kidney replacement therapy by over 26 years.

This lecture emphasizes the urgent need for early detection and intervention in CKD, noting that even mild cases require prompt action, including consideration of SGLT2 inhibitors like empagliflozin, which have demonstrated the potential to significantly delay kidney replacement therapy by over 26 years.

Heart failure with preserved ejection fraction (HFpEF) is becoming the predominant form of heart failure (HF), yet it is often underdiagnosed in clinical practice.1,2 In a recent webinar, Professor Andrew J. Stewart Coats from the Heart Research Institute, Sydney, Australia, underscored the urgent

Wach the lecture presented by Professor Christoph Wanner emphasizes the importance of early diagnosis and treatment of chronic kidney disease (CKD), particularly in patients with cardiovascular comorbidities, advocating for comprehensive screening methods and timely treatment to improve patient outcomes.

This lecture by Professor Christoph Wanner emphasizes the importance of early diagnosis and treatment of chronic kidney disease (CKD), particularly in patients with cardiovascular comorbidities, advocating for comprehensive screening methods and timely treatment to improve patient outcomes.

Heart failure is often underrecognized despite early warning signs. Delays in diagnosis and appropriate treatment can significantly worsen prognosis. By the time a patient is hospitalized for HF, the risk of rehospitalization and mortality has greatly increased. In this webinar, Professor Javed Butler  discussed data on the use of empagliflozin in HF patients, highlighting the benefits of early initiation in both chronic and acute settings as reflected by the latest guidelines. He also emphasized that medications such as sodium-glucose cotransporter 2 inhibitors exert a comprehensive impact across diverse cardio-renal-metabolic (CRM) conditions due to their direct and indirect actions, which collectively offer risk reduction across these interconnected disease states.

Cardio-kidney-metabolic (CKM) diseases often coexist in patients and are intimately linked with one another. Chronic kidney disease (CKD), heart failure (HF) and type 2 diabetes mellitus (T2D) form a triad of CKM conditions with major comorbidity, leading to compounded adverse outcomes.